UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
Randomized, double-blind phase III study of Pazopanib vs Placebo in subjects with metastatic renal cell carcinoma who have no evidence of disease following metastatectomy

Participants in this research study have metastatic renal cell carcinoma and have recently had surgery to remove the areas of cancer recurrence. The purpose of this study is to determine whether taking an oral drug known as pazopanib (Votrient®) will reduce the risk of the cancer recurring in the future.

Pazopanib is approved by the U.S. Food and Drug Administration (FDA) for subjects who have metastatic renal cell carcinoma. However, it has not been tested in subjects who have had all visible areas of their cancer removed surgically, and is considered experimental (not approved by the FDA) in this situation. Investigators don't know if pazopanib will be helpful to subjects in this scenario. There is currently no standard of care for subjects in this situation but careful observation without treatment is considered reasonable.

Approximately 14 people will take part in this study conducted by investigators at the University of Iowa. About 180 people may take part in this study nationwide.

Start Date
November 8, 2012
End Date
November 8, 2022
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Daniel Vaena, MD
Contact Info

Clarine Halvorsen, 319-356-3944

cancer ; ECOG E2810 ; IRB#201210741 ; metastatic renal cell carcinoma ; pazopanib (Votrient®) ; phase 3 ; phase III ; vaena ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.